TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 174nMAssay Description:Displacement of H3K14Ac from BAZ2B (unknown origin) preincubated for 30 mins with non-biotinylated peptide followed by addition of biotinylated pepti...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 360nMAssay Description:Competitive binding affinity to His-tagged BRAZ2B (unknown origin) expressed in Escherichia coli BL21(DE3) cells by AlphaScreen assay in presence of ...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 370nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 410nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 430nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 540nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 610nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 670nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 820nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 840nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: >1.00E+3nMAssay Description:Inhibition of human BAZ2B (S2054 to S2168 residues) expressed in bacterial expression system by BROMOscan assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: >1.00E+3nMAssay Description:Inhibition of human BAZ2B (S2054 to S2168 residues) expressed in bacterial expression system by BROMOscan assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.30E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.50E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.69E+3nMAssay Description:Inhibition of biotinylated-H4KAc4 binding to human His6-tagged BAZ2B (S1858 to S1972 residues) expressed in Escherichia coli BL21(DE3) after 2.5 hrs ...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.90E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.90E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 3.60E+3nMAssay Description:Binding affinity to human partial length BAZ2B expressed in bacterial expression system by BROMOscan assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 3.60E+3nMAssay Description:Binding affinity to human partial length BAZ2B expressed in bacterial expression system by BROMOscan assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 3.80E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 4.10E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 7.00E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 8.55E+3nMAssay Description:Competitive binding affinity to His-tagged BRAZ2B (unknown origin) expressed in Escherichia coli BL21(DE3) cells by AlphaScreen assay in presence of ...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 9.00E+3nMAssay Description:Displacement of biotinylated H3Kac14 peptide from His6-tagged human BAZ2B expressed in Escherichia coli BL21(DE3) after 30 mins by AlphaLISA assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 9.80E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.20E+4nMAssay Description:Displacement of biotinylated H3Kac14 peptide from His6-tagged human BAZ2B expressed in Escherichia coli BL21(DE3) after 30 mins by AlphaLISA assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.22E+4nMAssay Description:Inhibition of biotinylated-H4KAc4 binding to human His6-tagged BAZ2B (S1858 to S1972 residues) expressed in Escherichia coli BL21(DE3) after 2.5 hrs ...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.25E+4nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.40E+4nMAssay Description:Displacement of biotinylated H3Kac14 peptide from His6-tagged human BAZ2B expressed in Escherichia coli BL21(DE3) after 30 mins by AlphaLISA assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: >1.80E+4nMAssay Description:Displacement of biotinylated histone H3K14 peptide ligand from human recombinant His-tagged BAZ2B measured after 10 mins by TR-FRET assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: >2.00E+4nMAssay Description:Displacement of biotinylated histone H3K14 peptide ligand from human recombinant His-tagged BAZ2B measured after 10 mins by TR-FRET assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: >2.00E+4nMAssay Description:Displacement of biotinylated ligand from recombinant His-tagged BAZ2B (unknown origin) measured after 10 mins by TR-FRET assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: >2.00E+4nMAssay Description:Displacement of biotinylated ligand from recombinant His-tagged BAZ2B (unknown origin) measured after 10 mins by TR-FRET assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: >2.00E+4nMAssay Description:Inhibition of biotinylated-H4KAc4 binding to human His6-tagged BAZ2B (S1858 to S1972 residues) expressed in Escherichia coli BL21(DE3) after 2.5 hrs ...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: >2.00E+4nMAssay Description:Inhibition of biotinylated-H4KAc4 binding to human His6-tagged BAZ2B (S1858 to S1972 residues) expressed in Escherichia coli BL21(DE3) after 2.5 hrs ...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: >2.00E+4nMAssay Description:Inhibition of biotinylated-H4KAc4 binding to human His6-tagged BAZ2B (S1858 to S1972 residues) expressed in Escherichia coli BL21(DE3) after 2.5 hrs ...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: >2.00E+4nMAssay Description:Inhibition of biotinylated-H4KAc4 binding to human His6-tagged BAZ2B (S1858 to S1972 residues) expressed in Escherichia coli BL21(DE3) after 2.5 hrs ...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: >2.00E+4nMAssay Description:Inhibition of biotinylated-H4KAc4 binding to human His6-tagged BAZ2B (S1858 to S1972 residues) expressed in Escherichia coli BL21(DE3) after 2.5 hrs ...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: >2.00E+4nMAssay Description:Inhibition of biotinylated-H4KAc4 binding to human His6-tagged BAZ2B (S1858 to S1972 residues) expressed in Escherichia coli BL21(DE3) after 2.5 hrs ...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 2.27E+4nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 2.40E+4nMAssay Description:Displacement of biotinylated H3Kac14 peptide from His6-tagged human BAZ2B expressed in Escherichia coli BL21(DE3) after 30 mins by AlphaLISA assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 2.50E+4nMAssay Description:Displacement of biotinylated H3Kac14 peptide from His6-tagged human BAZ2B expressed in Escherichia coli BL21(DE3) after 30 mins by AlphaLISA assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 2.60E+4nMAssay Description:Displacement of biotinylated H3Kac14 peptide from His6-tagged human BAZ2B expressed in Escherichia coli BL21(DE3) after 30 mins by AlphaLISA assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 2.70E+4nMAssay Description:Competitive binding affinity to His-tagged BRAZ2B (unknown origin) expressed in Escherichia coli BL21(DE3) cells by AlphaScreen assay in presence of ...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: <3.16E+4nMAssay Description:Inhibition of BAZ2B (unknown origin) by BROMOscan assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 3.41E+4nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2B expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 3.60E+4nMAssay Description:Displacement of biotinylated H3Kac14 peptide from His6-tagged human BAZ2B expressed in Escherichia coli BL21(DE3) after 30 mins by AlphaLISA assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2B(Homo sapiens (Human))
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 3.70E+4nMAssay Description:Displacement of biotinylated H3Kac14 peptide from His6-tagged human BAZ2B expressed in Escherichia coli BL21(DE3) after 30 mins by AlphaLISA assayMore data for this Ligand-Target Pair